DoMaRe – N-CITE
DoMaRe – N-CITE
New Caspase-8 Inhibitors for Infection Treatment through Enhancement of Host Innate Immunity
Development of Monitoring and Analysis Research Ecosystem (DoMaRe)
Project Overview
DoMaRe is a multidisciplinary research initiative supported by the Italian National Programme for Research, Innovation and Competitiveness (PN RIC 2021–2027).
Within Work Package 6 (WP6 – TECMARE), dedicated to innovative cell-based therapeutics and drug delivery, Scylla Biotech S.r.l. is responsible for the N-CITE research activity.
N-CITE aims to develop innovative host-directed therapeutic approaches to difficult-to-treat infections by investigating selective inhibitors of caspase-8, a key regulator of cell death and inflammatory signalling.
Scientific Background
Antimicrobial resistance represents a major challenge for global health, highlighting the need for therapeutic strategies that complement conventional antimicrobial treatments.
Previous experimental studies have demonstrated that pharmacological modulation of caspase-8 can enhance neutrophil-mediated innate immune responses and improve host resistance to bacterial infections in preclinical models.
Building on this scientific foundation, N-CITE investigates the therapeutic potential of new caspase-8 inhibitors with improved selectivity and safety profiles.
Rather than targeting pathogens directly, this strategy seeks to strengthen the host's natural immune defence mechanisms.
Research Objectives
The main objectives of N-CITE are:
To identify and characterize novel small-molecule inhibitors of caspase-8.
To assess their inhibitory activity, selectivity and potential toxicity.
To investigate their ability to modulate neutrophil-associated innate immune responses.
To evaluate their therapeutic potential in preclinical models of infection.
Research Activities
The research programme integrates molecular pharmacology, immunology and experimental microbiology through three complementary stages.
1. Identification of candidate compounds
Discovery and preliminary characterization of molecules with potential caspase-8 inhibitory activity.
2. Biological characterization
Evaluation of candidate compounds through biochemical and cellular studies, with particular attention to immune modulation, selectivity and safety.
3. Preclinical evaluation
Investigation of the most promising candidates in relevant experimental models to assess their potential as host-directed anti-infective agents.
Scientific Team
Prof. Concetta Beninati – Principal Investigator and Scientific Coordinator
Scientific supervision, research strategy, coordination of project activities and interaction with collaborating institutions.
Prof. Giuseppe Teti – Scientific Team Member
Contribution to experimental design, molecular studies, data analysis and scientific quality control.
Additional scientific and technical personnel will contribute to the planned research activities according to the project's implementation programme.
Expected Outcomes and Impact
N-CITE is expected to contribute to the identification and preclinical characterization of novel caspase-8 inhibitors, providing new insights into the pharmacological modulation of innate immunity.
The project aims to advance the development of host-directed therapeutic strategies that could complement existing approaches to antimicrobial treatment.
By integrating drug discovery and immunological research, N-CITE contributes to the broader objectives of DoMaRe in biomedical innovation and translational research.
Project Information
Programme: PN RIC 2021–2027 – Research, Innovation and Competitiveness for the Green and Digital Transition
Action: 1.1.2 – Strategic Research Supply Chains
Project: DoMaRe – Development of Monitoring and Analysis Research Ecosystem
Work Package: WP6 – TECMARE
Scylla Research Activity: N-CITE
Project Code: 2615_QIIR112_00065
CUP: B49H26000020005
Duration: 30 months
Scylla Biotech Project Budget: €250,000
Beneficiary: Scylla Biotech S.r.l.
Funding: PN RIC 2021–2027, co-financed by the European Union through the European Regional Development Fund (ERDF).
Scientific results and project updates will be added as the research activities progress.